MedTrace Logo

A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema

NCT00439179 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2020-02-17

Study results available
· View outcomes & findings →

Summary

A Phase I Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema

Conditions

Interventions

DRUG

cohort 1

Weekly gem + GW572016, 1000mg/day (combination)

DRUG

cohort 2

Weekly gem + GW572016, 1500 mg/day (combination)

DRUG

cohort 3

GEMOX + GW572016 1000 mg/day (combination)

DRUG

cohort 4

GEMOX + GW572016 1500 mg/day (combination)

Sponsors & Collaborators

Principal Investigators

  • howard Safran, MD · Brown University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00439179 on ClinicalTrials.gov